{"id":7230,"date":"2020-03-03T17:56:49","date_gmt":"2020-03-04T01:56:49","guid":{"rendered":"https:\/\/www.bluerocktx.com\/?p=7230"},"modified":"2023-06-26T14:32:53","modified_gmt":"2023-06-26T18:32:53","slug":"bluerock-therapeutics-appoints-seth-ettenberg-ph-d-chief-scientific-officer","status":"publish","type":"post","link":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-appoints-seth-ettenberg-ph-d-chief-scientific-officer\/","title":{"rendered":"BlueRock Therapeutics Appoints Seth Ettenberg, Ph.D. Chief Scientific Officer"},"content":{"rendered":"
CAMBRIDGE, Mass., March 03, 2020 (GLOBE NEWSWIRE)<\/strong> \u2014 BlueRock Therapeutics, LP today announced the addition of Seth Ettenberg, Ph.D. to the company\u2019s senior leadership team. In his role as Chief Scientific Officer, Dr. Ettenberg will oversee BlueRock\u2019s research and discovery efforts, focused on the application and expansion of BlueRock\u2019s\u00a0cell+gene<\/em><\/strong>\u00a0platform to the creation of engineered cellular medicines.<\/p>\n \u201cWe are thrilled to have Seth join our team. He brings deep domain expertise in cell therapy and a track record of building and leading high-performance teams in both large pharma and start-up biotech companies,\u201d said Emile Nuwaysir, Ph.D., President and CEO, BlueRock Therapeutics. \u201cHe is an accomplished discovery scientist with a true entrepreneurial spirit. I look forward to working closely with him to advance BlueRock\u2019s mission to create a new class of authentic cellular medicines to reverse devastating diseases for patients in need.\u201d<\/p>\n \u201cI believe that BlueRock\u2019s\u00a0cell+gene<\/em><\/strong>\u00a0platform will be truly transformational to the industry and of genuine benefit to patients,\u201d said Dr. Ettenberg. \u201cHaving spent my career advancing disruptive technologies, I am very excited to be joining the team to help realize the full potential of the platform and advance a new wave of therapeutic cellular medicine.\u201d<\/p>\n Prior to joining BlueRock, Dr. Ettenberg was a founding member of the Unum Therapeutics team, where he served as Chief Scientific Officer. In this role, Dr. Ettenberg built and led teams across the organization that brought several novel cellular therapies from invention to clinical testing. Prior to that, Dr. Ettenberg headed the Cambridge Site of Novartis\u2019 Oncology Biotherapeutics, leading strategy, innovation, and implementation of drug development projects of Novartis Institutes for Biomedical Research (NIBR). He also previously served as a Project Leader and Senior Research Scientist at CuraGen.<\/p>\n About BlueRock Therapeutics<\/strong>
\nBlueRock Therapeutics, a wholly owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics\u2019\u00a0cell+gene<\/em><\/strong>\u00a0platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock Therapeutics\u2019 cell differentiation technology recapitulates the cell\u2019s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock\u2019s culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit\u00a0www.bluerocktx.com<\/span><\/a>.<\/p>\n